Clinical Trial Update: Short-Course Radiotherapy, Nal-IRI, Capecitabine, and Camrelizumab for Locally Advanced MSS Rectal Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating short-course radiotherapy in combination with nal-IRI (nanoliposomal irinotecan), capecitabine, and camrelizumab for locally advanced m…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rectal Cancer

Drugs mentioned

• Camrelizumab (camrelizumab)
• Capecitabine (capecitabine)
• Nal-IRI (nanoliposomal irinotecan)

Snippet

Sponsor: Guangdong Provincial People's Hospital | Conditions: Rectal Cancer Patients | Phase 2 | Status: NOT_YET_RECRUITING